January 10, 2025 – Talk Bio

Insilico Medicine and Menarini Group’s Stemline Therapeutics Announce Second Exclusive Licensing Agreement for AI-Discovered Oncology Drug Candidate

5 months ago talkbio0Tagged AI-generated cancer, Groups, Insilico Medicine, Menarini, Oncology drug candidate, Stemline

Insilico Medicine, Menarini Group, Stemline Therapeutics, AI-generated cancer drug, Oncology drug candidate, Licensing agreement, $550 million deal

Light Horse Therapeutics Secures $62M Series A Funding and Partners with Novartis for Cancer Therapies

5 months ago talkbio0Tagged Cancer Therapeutic Procedure, Funding, genetic editing, Light Horse, Novartis, Precision - temporal, Series, small molecule therapeutics

Light Horse Therapeutics, Novartis, Series A funding, cancer therapies, small molecule therapeutics, precision genetic editing platform

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

5 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy

Repare Therapeutics Advances to Phase 3 Cancer Combo Trial Following Successful MYTHIC Trial Outcomes

5 months ago talkbio0Tagged camonsertib, cancer combo trial, cost-effective clinical trials, lunresertib, Malignant neoplasm of endometrium, MYTHIC, Phase 3 trial, Platinum-Resistant Ovarian Carcinoma, Repare

Repare Therapeutics, Phase 3 trial, cancer combo trial, MYTHIC trial, lunresertib, camonsertib, endometrial cancer, platinum-resistant ovarian cancer, cost-effective clinical trials